suprecur 0.15 mg/annos nenäsumute, liuos
sanofi oy - buserelini acetas - nenäsumute, liuos - 0.15 mg/annos - busereliini
suprefact injektioneste
sanofi-aventis oy - buserelini acetas - injektioneste - busereliini
suprefact 0.1 mg/annos nenäsumute
sanofi-aventis oy - buserelini acetas - nenäsumute - 0.1 mg/annos - busereliini
suprefact depot 6.3 mg implantaatti
sanofi-aventis oy - buserelini acetas - implantaatti - 6.3 mg - busereliini
suprecur depot 3.6 mg injektiokuiva-aine ja liuotin, suspensiota varten
sanofi-aventis oy - buserelini acetas - injektiokuiva-aine ja liuotin, suspensiota varten - 3.6 mg - busereliini
suprefact depot 9.45 mg implantaatti
sanofi oy - buserelini acetas - implantaatti - 9.45 mg - busereliini
veterelin vet 0.004 mg/ml injektioneste, liuos
laboratorios calier s.a. - buserelini acetas - injektioneste, liuos - 0.004 mg/ml - busereliini
porceptal vet 4 mikrog/ml injektioneste, liuos
intervet international b.v. - buserelini acetas - injektioneste, liuos - 4 mikrog/ml - busereliini
leuprorelin sandoz 5 mg implantaatti, esitäytetty ruisku
sandoz a/s - leuprorelin acetate - implantaatti, esitäytetty ruisku - 5 mg - leuproreliini
firmagon
ferring pharmaceuticals a/s - degareliksia - prostatiset kasvaimet - endokriinihoito - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.